BACKGROUND: The TAM receptors (tyro3, axl and mer) and their ligands (vitamin K-dependent proteins-Gas6 and Protein S) are crucial modulators of inflammation, which may be relevant in chronic kidney disease (CKD). Gas6 and axl have multiple roles in mediating vascular atherosclerosis and injury, thrombosis and inflammation, yet nothing is known about the Gas6-axl pathway in humans with CKD. Given the prevalence of chronic inflammation and vascular disease in this population, we measured TAM ligands in patients with various levels of renal function. METHODS: Gas6 and protein S were quantified in the plasma by ELISA in three patient groups: end-stage renal disease on chronic hemodialysis (HD), CKD and normal controls. RESULTS: Significantly increased levels of Gas6 and protein S were found in CKD patients compared with normal controls (P < 0.01 and <0.001, respectively). In HD patients, Gas6 levels were elevated compared with controls (P < 0.001) and positively associated with low albumin (r = 0.33; P = 0.01), dialysis vintage (r = 0.36; P = 0.008) and IV iron administration (r = 0.33; P = 0.01). The levels of Gas6 rose with CKD stage and were inversely associated with estimated GFR (P < 0.0001). CONCLUSIONS: Dysregulation of circulating Gas6 is associated with renal disease and inversely proportional to renal function. Low albumin and higher IV iron administration were associated with higher Gas6 levels, suggesting a possible connection between inflammation and oxidative stress mediated by iron. Protein S levels were also elevated in CKD patients, but the relevance of this finding needs to be further investigated.
BACKGROUND: The TAM receptors (tyro3, axl and mer) and their ligands (vitamin K-dependent proteins-Gas6 and Protein S) are crucial modulators of inflammation, which may be relevant in chronic kidney disease (CKD). Gas6 and axl have multiple roles in mediating vascular atherosclerosis and injury, thrombosis and inflammation, yet nothing is known about the Gas6-axl pathway in humans with CKD. Given the prevalence of chronic inflammation and vascular disease in this population, we measured TAM ligands in patients with various levels of renal function. METHODS:Gas6 and protein S were quantified in the plasma by ELISA in three patient groups: end-stage renal disease on chronic hemodialysis (HD), CKD and normal controls. RESULTS: Significantly increased levels of Gas6 and protein S were found in CKDpatients compared with normal controls (P < 0.01 and <0.001, respectively). In HDpatients, Gas6 levels were elevated compared with controls (P < 0.001) and positively associated with low albumin (r = 0.33; P = 0.01), dialysis vintage (r = 0.36; P = 0.008) and IV iron administration (r = 0.33; P = 0.01). The levels of Gas6 rose with CKD stage and were inversely associated with estimated GFR (P < 0.0001). CONCLUSIONS: Dysregulation of circulating Gas6 is associated with renal disease and inversely proportional to renal function. Low albumin and higher IV iron administration were associated with higher Gas6 levels, suggesting a possible connection between inflammation and oxidative stress mediated by iron. Protein S levels were also elevated in CKDpatients, but the relevance of this finding needs to be further investigated.
Authors: A Angelillo-Scherrer; P de Frutos; C Aparicio; E Melis; P Savi; F Lupu; J Arnout; M Dewerchin; M Hoylaerts; J Herbert; D Collen; B Dahlbäck; P Carmeliet Journal: Nat Med Date: 2001-02 Impact factor: 53.440
Authors: Vincenzo Panichi; Massimiliano Migliori; Stefano De Pietro; Daniele Taccola; Anna Maria Bianchi; Luca Giovannini; Maria Norpoth; Maria Rita Metelli; Renza Cristofani; Alberto A E Bertelli; Giulietta Sbragia; Ciro Tetta; Roberto Palla; R Colombo Journal: Nephron Date: 2002-08 Impact factor: 2.847
Authors: Anette Fiebeler; Joon-Keun Park; Dominik N Muller; Carsten Lindschau; Michael Mengel; Saskia Merkel; Bernhard Banas; Friedrich C Luft; Hermann Haller Journal: Am J Kidney Dis Date: 2004-02 Impact factor: 8.860
Authors: Michael G Shlipak; Linda F Fried; Casey Crump; Anthony J Bleyer; Teri A Manolio; Russell P Tracy; Curt D Furberg; Bruce M Psaty Journal: Circulation Date: 2003-01-07 Impact factor: 29.690
Authors: Eric L Knight; Eric B Rimm; Jennifer K Pai; Kathryn M Rexrode; Carolyn C Cannuscio; JoAnn E Manson; Meir J Stampfer; Gary C Curhan Journal: J Am Soc Nephrol Date: 2004-07 Impact factor: 10.121
Authors: Jun Wu; Carl Ekman; Andreas Jönsen; Gunnar Sturfelt; Anders A Bengtsson; Anders Gottsäter; Bengt Lindblad; Elisabet Lindqvist; Tore Saxne; Björn Dahlbäck Journal: Arthritis Res Ther Date: 2011-04-15 Impact factor: 5.156
Authors: Lucas M Ferrer; Alexandra M Monroy; Jahaira Lopez-Pastrana; Gayani Nanayakkara; Ramon Cueto; Ya-Feng Li; Xinyuan Li; Hong Wang; Xiao-Feng Yang; Eric T Choi Journal: J Cardiovasc Transl Res Date: 2016-02-29 Impact factor: 4.132
Authors: Justin P Van Beusecum; Natalia R Barbaro; Charles D Smart; David M Patrick; Roxana Loperena; Shilin Zhao; Nestor de la Visitacion; Mingfang Ao; Liang Xiao; Cyndya A Shibao; David G Harrison Journal: Circ Res Date: 2021-09-27 Impact factor: 23.213
Authors: Pedro Recarte-Pelz; Dolors Tàssies; Gerard Espinosa; Begoña Hurtado; Núria Sala; Ricard Cervera; Joan Carles Reverter; Pablo García de Frutos Journal: Arthritis Res Ther Date: 2013-03-12 Impact factor: 5.156
Authors: Gareth D Hyde; Rebecca F Taylor; Nick Ashton; Samantha J Borland; Hon Sing Geoffrey Wu; Andrew P Gilmore; Ann E Canfield Journal: PLoS One Date: 2014-07-14 Impact factor: 3.240